Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.

Morizane, C. 1,*; Okusaka, T. 1; Mizusawa, J. 2; Katayama, H. 2; Ueno, M. 3; Ikeda, M. 4; Ozaka, M. 5; Okano, N. 6; Sugimori, K. 7; Fukutomi, A. 8; Hara, H. 9; Mizuno, N. 10; Yanagimoto, H. 11; Wada, K. 12; Tobimatsu, K. 13; Yane, K. 14; Nakamori, S. 15; Yamaguchi, H. 16; Asagi, A. 17; Yukisawa, S. 18; Kojima, Y. 19; Kawabe, K. 20; Kawamoto, Y. 21; Sugimoto, R. 22; Iwai, T. 23; Nakamura, K. 24; Miyakawa, H. 25; Yamashita, T. 26; Hosokawa, A. 27; Ioka, T. 28; Kato, N. 29; Shioji, K. 30; Shimizu, K. 31; Nakagohri, T. 32; Kamata, K. 33; Ishii, H. 34; Furuse, J. 6; on behalf of the members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)

[Article]
Annals of Oncology.
30(12):1950-1958, December 2019.

(Format: HTML)